elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Pricing
Log in
Sign up
Home
/
Subjects
/
Lung cancer
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Lung cancer
RIS
0.012
(Research Intensity Score)
Papers
1676
Top papers
The global burden of lung cancer: current status and future trends
2023 · 1441 citations
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
2022 · 2627 citations
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
2023 · 1084 citations
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
2025 · 214 citations
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
2023 · 670 citations
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
2021 · 1497 citations
Small Cell Lung Cancer
2025 · 158 citations
Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
2025 · 109 citations
Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions
2023 · 351 citations
Newest papers
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
2026 · 14 citations
Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005
2026 · 11 citations
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
2025 · 214 citations
Small Cell Lung Cancer
2025 · 158 citations
Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
2025 · 109 citations
Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study
2025 · 115 citations
Neoadjuvant Osimertinib for Resectable EGFR -Mutated Non–Small Cell Lung Cancer
2025 · 74 citations
Particulate matter air pollution as a cause of lung cancer: epidemiological and experimental evidence
2025 · 80 citations
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
2025 · 59 citations
Browse all papers →
Lung cancer's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Lung cancer's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link